Nurix Therapeutics Q4 EPS $(0.77) Misses $(0.57) Estimate, Sales $15.16M Miss $22.26M Estimate
Portfolio Pulse from Happy Mohamed
Nurix Therapeutics (NASDAQ:NRIX) reported Q4 earnings with a per-share loss of $(0.77), missing the $(0.57) estimate, and sales of $15.16M, missing the $22.26M estimate. Despite these misses, the company saw an 11.49% decrease in losses and a 123.49% increase in sales compared to the same period last year.
February 15, 2024 | 9:18 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Nurix Therapeutics reported a larger-than-expected Q4 loss of $(0.77) per share and lower sales of $15.16M, missing the consensus estimates.
Missing both EPS and revenue estimates significantly, especially by 35.09% for EPS and 31.90% for revenue, is likely to negatively impact investor sentiment and could lead to a short-term decrease in stock price. However, the year-over-year improvement in both losses and sales might offer some mitigation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100